Latest Conference Articles

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of Braftovi, Erbitux and chemotherapy showed promising antitumor activity.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.

Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations significantly improved results.

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows.

An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.

In patients with HR-positive breast cancer who recently gave birth, breastfeeding is OK during a break from receiving hormone therapy.

Patients with metastatic disease whose cancers were tested and treated for specific mutations tended to have better outcomes than those given the standard of care.

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with Imfinzi versus placebo.

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer.

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and -ultralow metastatic breast cancer.

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated metastatic colorectal cancer.

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta followed by response-guided chemotherapy experienced “exceptionally excellent” survival outcomes.

Hypofractionated radiation was noninferior to normofractionated radiation in patients with early breast cancer regarding lymphedema risk.

Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus chemotherapy and postsurgical Keytruda.

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Adding Zynyz to carboplatin and paclitaxel prolonged survival without progression in chemotherapy-naive recurrent or metastatic squamous cell carcinoma of the anal canal.

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment.

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial chemoembolization.

Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy.

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.

Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression.

Patients with HER2-positive breast cancer benefitted from treatment with Enhertu regardless of brain metastasis.

Among patients with previously treated advanced clear cell renal cell carcinoma (RCC) Welireg continued to show some benefits, though not to overall survival.

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.